Galapagos announced it could not find a buyer for its cell therapy unit and will wind down the business, a decision that will lead to the closure of facilities in Europe, China and the U.S. and threaten roughly 365 jobs. The company said offers received were primarily financial and lacked the financing needed to sustain the unit. The exit marks a rapid strategic reversal less than a year after Galapagos invested in cell therapy capabilities and underscores the difficulty of sustaining capital‑intensive cell therapy operations without committed strategic partners. The move will shift company resources back to core programs, but it also raises questions about vendor commitments, patient follow‑up for ongoing trials, and commercial obligations tied to the unit’s closure.